Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
151-165 of 4028 results
Trevi Therapeutics unveils positive results from phase 2 trial in prurigo nodularis
Trevi Therapeutics, which is developing oral Nalbuphine®ER for chronic pruritus conditions, announced positive results from its phase 2 trial for the treatment of moderate to severe prurigo nodularis.
Contract Research & Services > Clinical Trials > News
ProMetic's PBI-4050 significantly reduces liver fibrosis in alström syndrome patients
ProMetic Life Sciences announced that the Drug Safety Monitoring Board (DSMB) recommended that patient enrollment should continue in its ongoing Alström syndrome phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
BIOCAD Biotechnology begins phase 2 clinical trials of psoriasis drug
BIOCAD Biotechnology has started phase 2 clinical trials of a drug to treat severe psoriasis.
Contract Research & Services > Clinical Trials > News
Nymox unveils successful phase 3 long-term fexapotide repeat injection BPH trial results
Nymox Pharmaceutical has reported successful new study results from the long-term repeated injection group from the US Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.
Contract Research & Services > Clinical Trials > News
Pfizer's drug improves survival in kidney cancer study
Pfizer has unveiled results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating SUTENT (sunitinib) as adjuvant therapy.
Contract Research & Services > Clinical Trials > News
Transgene partners with Merck, Pfizer for head and neck cancer trial
French gene therapy firm Transgene has partnered with Merck and Pfizer to evaluate a potential new combination treatment for head and neck cancer.
Contract Research & Services > Clinical Trials > News
Aprea enrolls first patients in phase II study of APR-246 to treat high-grade serous ovarian cancer
Aprea Therapeutics AB has enrolled the first patients in the Phase II part of the ongoing clinical study of APR-246 for the treatment of high-grade serous ovarian cancer.
Contract Research & Services > Clinical Trials > News
Scancell intends to develop SCIB2 for treatment of lung cancer
By PBR Staff Writer
Cancer immunotherapies developer Scancell said it intends to develop its SCIB2 ImmunoBody for the treatment of non-small-cell lung cancer and is preparing clinical trials in line with this goal.
Contract Research & Services > Clinical Trials > News
Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors
Biopharmaceutical firm Exelixis has announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.
Contract Research & Services > Clinical Trials > News
Kite Pharma starts phase 1b/2 combination study for KTE-C19 and atezolizumab in refractory DLBCL
Kite Pharma has enrolled first patient in ZUMA-6, a phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech's anti-PD-L1 cancer immunotherapy.
Contract Research & Services > Clinical Trials > News
FDA accepts Velicept's IND to start phase I study for solabegron
The US Food and Drug Administration (FDA) has accepted Velicept Therapeutics' Investigational New Drug (IND) application to initiate a Phase I pharmacokinetic study for a once-daily formulation for solabegron.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Brilinta heart drug fails in peripheral artery disease trial
By PBR Staff Writer
AstraZeneca’s heart drug, Brilinta, has failed to show benefit over a generic blood thinner in patients with peripheral artery disease.
Contract Research & Services > Clinical Trials > News
Theravance doses first patient in phase 1b trial of TD-1473 in moderate to severe ulcerative colitis
Theravance Biopharma has dosed the first patient in a Phase 1b clinical trial of TD-1473 in patients with moderate to severe ulcerative colitis.
Contract Research & Services > Clinical Trials > News
Novartis' Cosentyx demonstrates long-lasting skin clearance in plaque psoriasis
Novartis has said that more than 66% of patients treated with Cosentyx (secukinumab) achieved clear or almost clear skin after four years.
Contract Research & Services > Clinical Trials > News
Janssen's Guselkumab beats Humira in psoriasis study
Janssen Research & Development (Janssen) announced findings from the first of three pivotal Phase 3 studies evaluating guselkumab, a subcutaneously administered anti-interleukin (IL)-23 monoclonal antibody in late-stage development for the treatment of adults with moderate to severe plaque psoriasis.
Contract Research & Services > Clinical Trials > News
151-165 of 4028 results